Introduction
Methods
Data source
Brand (where applicable) | Content in molecule(s) | Patients |
V%
| MPR > 80% |
---|---|---|---|---|
Actokit ® | Risedronic acid 35 mg weekly and calcium 6 days | 4,954 | 4.7% | 93.1%a
|
Actonel ® 35 mg | Risedronic acid 35 mg weekly | 24,866 | 23.6% | 91.5%b
|
Actonel ® 5 mg | Risedronic acid 5 mg daily | 1,010 | 1.0% | 91.6%b
|
Alendronic acid 10 mg | Alendronic acid 10 mg daily branded or generic | 3,101 | 2.9% | 92.2%a
|
Alendronic acid 70 mg | Alendronic acid 70 mg weekly branded or generic | 55,195 | 52.3% | 91.2%b
|
Bonviva ® tablet | Ibandronic acid 150 mg monthly | 3,279 | 3.1% | 89.0%c
|
Didrokit ® | Etidronic acid cyclic and calcium | 2,538 | 2.4% | 85.7%c
|
Evista ® | Raloxifene 60 mg daily | 1,331 | 1.3% | 91.5%b
|
Fosavance ® | Alendronic acid 70 mg weekly & 2,800 IU vitamin D3 | 8,279 | 7.8% | 92.3%a
|
Protolos ® | Strontium ranelate 2 g daily | 953 | 0.9% | 79.1%c
|
Total of ten products | 105,506 | 100.0% | 91.2% |
Compliance
Persistence
Determinants of persistence
Follow-up of stoppers
Statistical analysis
Results
Compliance
Persistence
Patients |
V%
| Persistence | Adj.OR (95% CI)a
| |
---|---|---|---|---|
Total (n, V%) | 8,626 | 43.1% | ||
Age | ||||
1, < = 60 | 2,092 | 24.3% | 36.1% | Reference |
2, 61–70 | 2,059 | 23.9% | 45.1% | 1.41 (1.23–1.61) |
3, 71–80 | 2,591 | 30.0% | 45.7% | 1.51 (1.33–1.73) |
4, > = 81 | 1,884 | 21.8% | 44.9% | 1.64 (1.42–1.90) |
Gender | ||||
Female | 6,900 | 80.0% | 43.9% | – |
Male | 1,726 | 20.0% | 39.7% | – |
Urbanization | ||||
1, very high (densely) | 2,464 | 28.6% | 37.9% | Reference |
2, high | 2,584 | 30.0% | 45.4% | 1.39 (1.23–1.56) |
3, moderate | 1,701 | 19.7% | 43.3% | 1.30 (1.13–1.49) |
4, low | 1,401 | 16.2% | 46.9% | 1.44 (1.25–1.66) |
5, very low (sparsely) | 476 | 5.5% | 45.5% | 1.37 (1.11–1.70) |
GP or specialist of start Rx | ||||
GP | 5,426 | 62.9% | 45.0% | – |
Specialist | 3,200 | 37.1% | 39.8% | – |
Start product | ||||
Risedronic ac. weekly and daily Ca | 747 | 8.7% | 42.4% | – |
Risedronic ac. 35 mg weekly | 1,818 | 21.1% | 45.4% | – |
Risedronic ac. 5 mg daily | 82 | 1.0% | 40.2% | – |
Alendronic ac. 10 mg daily | 241 | 2.8% | 23.2% | 0.31 (0.23–0.43) |
Alendronic ac. 70 mg weekly | 3,698 | 42.9% | 43.4% | – |
Ibandronic ac. 150 mg monthly | 443 | 5.1% | 46.3% | – |
Etidronate cyclic and daily Ca | 281 | 3.3% | 28.5% | 0.42 (0.32–0.56) |
Raloxifene 60 mg daily | 63 | 0.7% | 33.3% | 0.53 (0.31–0.92) |
Alendronic ac. 70 mg and vitD weekly | 965 | 11.2% | 52.7% | 1.41 (1.21–1.63) |
Strontium ranelate | 288 | 3.3% | 21.9% | 0.27 (0.20–0.36) |
Drug burden in lookback period | ||||
0 | 509 | 5.9% | 43.4% | excl. |
1, 2 | 2,584 | 30.0% | 43.1% | excl. |
3, 4 | 3,228 | 37.5% | 42.3% | excl. |
5+ | 2,305 | 37.4% | 44.0% | excl. |
Medication lookback period | ||||
With_any_medication | 8,153 | 94.5% | 43.1% | excl. |
Without_any_medication | 473 | 5.5% | 42.7% | excl. |
Osteoporosis | 1,221 | 14.2% | 43.3% | – |
Calcium and/or vit. D | 2,408 | 27.9% | 47.4% | 1.26 (1.13–1.39) |
Statins | 1,689 | 19.6% | 45.8% | – |
Cardiovascular medication | 4,551 | 52.8% | 44.0% | 0.88 (0.79–0.97) |
Anti-inflammatory | 2,537 | 29.4% | 46.1% | – |
Gastric protectors | 3,597 | 41.7% | 42.5% | – |
Asthma/COPD | 1,684 | 19.5% | 40.2% | – |
Diabetic medication | 793 | 9.2% | 45.1% | – |
Antidepressants | 961 | 11.1% | 42.2% | – |
Thyroid hormone | 570 | 6.6% | 41.4% | – |
Glucocorticoids | 2,685 | 31.1% | 37.6% | 0.65 (0.59–0.72) |
Medication trailing period | ||||
With_any_med | 7,083 | 82.1% | 51.9% | 9.31 (7.93–40.92) |
Without_any_med | 1,543 | 17.9% | 2.3% | Reference |